Dr. Hambly serves as the Head of Technology and Manufacturing, holding a doctorate in Biochemistry from Washington University in St. Louis and boasting more than 20 years of industry experience.

He played a pivotal role as the analytical lead for the first FDA-approved recombinant virus program, Imlygic®. At Kite Pharma, Dr. Hambly headed up the Analytical Development group and led the analytical team supporting the BLA approval for Yescarta®, supporting both viral vector and CAR-T product for one of the earliest approved CAR-T products.

Following this, Dr. Hambly held the position of Senior Director at Atara Biotherapeutics, where he directed analytics for both cell and vector processes, as well as vector process development and external manufacturing, ultimately leading to the EMA approval of Ebvalo.

Dr. Hambly established Advanced Therapy Product Consulting in 2019 and has worked with over 50 clients supporting venture capital due diligence, fundraising, IND and BLA filings, method and process validations, product comparability.  He also led technical operations for various start-ups and has worked with small, mid-sized, large biotech and Fortune 500 companies. Notably, he has supported over 20 IND filings and contributed to the approval of two first-in-class cell therapy products in 2025, along with a first-in-class gene therapy set to be approved in 2026.